AIRLINK 62.48 Increased By ▲ 2.05 (3.39%)
BOP 5.36 Increased By ▲ 0.01 (0.19%)
CNERGY 4.58 Decreased By ▼ -0.02 (-0.43%)
DFML 15.50 Increased By ▲ 0.66 (4.45%)
DGKC 66.40 Increased By ▲ 1.60 (2.47%)
FCCL 17.59 Increased By ▲ 0.73 (4.33%)
FFBL 27.70 Increased By ▲ 2.95 (11.92%)
FFL 9.27 Increased By ▲ 0.21 (2.32%)
GGL 10.06 Increased By ▲ 0.10 (1%)
HBL 105.70 Increased By ▲ 1.49 (1.43%)
HUBC 122.30 Increased By ▲ 4.78 (4.07%)
HUMNL 6.60 Increased By ▲ 0.06 (0.92%)
KEL 4.50 Decreased By ▼ -0.05 (-1.1%)
KOSM 4.48 Decreased By ▼ -0.09 (-1.97%)
MLCF 36.20 Increased By ▲ 0.79 (2.23%)
OGDC 122.92 Increased By ▲ 0.53 (0.43%)
PAEL 23.00 Increased By ▲ 1.09 (4.97%)
PIAA 29.34 Increased By ▲ 2.05 (7.51%)
PIBTL 5.80 Decreased By ▼ -0.14 (-2.36%)
PPL 107.50 Increased By ▲ 0.13 (0.12%)
PRL 27.25 Increased By ▲ 0.74 (2.79%)
PTC 18.07 Increased By ▲ 1.97 (12.24%)
SEARL 53.00 Decreased By ▼ -0.63 (-1.17%)
SNGP 63.21 Increased By ▲ 2.01 (3.28%)
SSGC 10.80 Increased By ▲ 0.05 (0.47%)
TELE 9.20 Increased By ▲ 0.71 (8.36%)
TPLP 11.44 Increased By ▲ 0.86 (8.13%)
TRG 70.86 Increased By ▲ 0.95 (1.36%)
UNITY 23.62 Increased By ▲ 0.11 (0.47%)
WTL 1.28 No Change ▼ 0.00 (0%)
BR100 6,941 Increased By 63.6 (0.92%)
BR30 22,802 Increased By 233 (1.03%)
KSE100 67,142 Increased By 594.3 (0.89%)
KSE30 22,090 Increased By 175.1 (0.8%)

Tough times call for resilient strategies! Who would agree to this better than the pharmaceutical manufacturers in Pakistan, who have been battling for years over irrational regulatory mechanisms. However, with little hopes for any transformation in industry’s dynamics, pharmaceutical companies have started unearthing alternative strategies to stay afloat.
In 1H FY14, aggregate profitability of the three leading companies in the pharmaceutical sector namely Glaxo, Abbott and Sanofi-–that represent nearly 80 percent of the total market capitalisation of this sector-–grew by a decent 10 percent year on year. Thanks to the sector’s strategy of diversifying into consumer health care and nutritional segments. However, at this stage, pharmaceutical business still continues to hold the largest share of the pie (70-80 percent share) in the portfolios of pharmaceutical manufacturers.
Sadly, pressures on input costs owing to rising fuelling inflation, rise in sales tax and levies, unfriendly currency movements have made the case difficult for pharmaceutical companies to sustain their gross margins. Hence, average gross margins of proxy pharmaceutical companies slipped downwards by 200 bps to 29 percent in 1H FY14.
Moreover, selling, distribution and marketing costs continue to inch upwards with the launch of new products and focus on alternative product lines, thus hampering the profitability further. This trend is likely to continue in coming years until alternative product lines attain a strong footprint in the market.
To put things in order, pharmaceutical industry has been going through a critical time. Absence of a rational pricing policy has not only hampered industry’s evolution, but also repressed existing players to invest further. Resultantly, Pakistan stands at an inferior position when compared to pharmaceutical industries in India and Bangladesh where regulations are less stringent giving players a level playing field to sustain and flourish. The solution to this, however, lies in implementing a coherent pricing policy in consultation with all the stakeholders.


======================================================
Pharma Sectors Combined P&L*
======================================================
Rs (mn) 1HCY14 1HCY13 Chng
======================================================
Sales 27,853 25,225 10%
Cost of Sales (19,694) (17,440) 13%
Gross Profit 8,159 7,785 5%
Selling, marketing and
distribution expenses (4,062) (3,875) 5%
Administrative expenses (804) (727) 11%
Other Income 569 466 22%
Other Expenses (307) (371) -17%
Operating Profit 3,555 3,278 8%
Finance cost (146) (123) 19%
Profit before taxation 3,409 3,155 8%
Taxation (1,257) (1,206) 4%
Profit after taxation 2,152 1,949 10%
EPS (Rs.) 19.08 23.84
======================================================

*Glaxo, Abbott and Sanofi

Source: Company Accounts

Comments

Comments are closed.